December 19, 2016 10:15 AM EST

Sanger spinout gets $10M, tackles the microbiome frontier; Adaptimmune and Bellicum partner T cell tech

Shehla Shakoor

Managing Director

The Sanger Institute has launched a new spinout dubbed Microbiotica, which is leaping into the hot microbiome field. The IP Group and Cambridge Innovation …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanger spinout gets $10M, tackles the microbiome frontier; Adaptimmune and Bellicum partner T cell tech

Shehla Shakoor

Managing Director

Sign up to read this article for free.

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Sanger spin­out gets $10M, tack­les the mi­cro­bio­me fron­tier; Adap­ti­m­mune and Bel­licum part­ner T cell tech

Shehla Shakoor

Managing Director

Sign up to read this article for free.

more like this

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Sanger spinout gets $10M, tackles the microbiome frontier; Adaptimmune and Bellicum partner T cell tech

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra